- Home
- CAG vs MDGL Comparison
CAG vs MDGL Comparison
Compare CAG & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAG
- MDGL
- Stock Information
- Founded
- CAG 1919
- MDGL 2011
- Country
- CAG United States
- MDGL United States
- Employees
- CAG N/A
- MDGL N/A
- Industry
- CAG Packaged Foods
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- CAG Consumer Staples
- MDGL Health Care
- Exchange
- CAG Nasdaq
- MDGL Nasdaq
- Market Cap
- CAG 9.3B
- MDGL 9.6B
- IPO Year
- CAG N/A
- MDGL N/A
- Fundamental
- Price
- CAG $17.16
- MDGL $423.00
- Analyst Decision
- CAG Hold
- MDGL Strong Buy
- Analyst Count
- CAG 11
- MDGL 12
- Target Price
- CAG $21.64
- MDGL $521.09
- AVG Volume (30 Days)
- CAG 11.3M
- MDGL 277.8K
- Earning Date
- CAG 12-18-2025
- MDGL 11-04-2025
- Dividend Yield
- CAG 8.05%
- MDGL N/A
- EPS Growth
- CAG 73.36
- MDGL N/A
- EPS
- CAG 1.77
- MDGL N/A
- Revenue
- CAG $11,450,500,000.00
- MDGL $515,547,000.00
- Revenue This Year
- CAG N/A
- MDGL $394.38
- Revenue Next Year
- CAG N/A
- MDGL $64.73
- P/E Ratio
- CAG $9.82
- MDGL N/A
- Revenue Growth
- CAG N/A
- MDGL 3421.98
- 52 Week Low
- CAG $17.35
- MDGL $213.71
- 52 Week High
- CAG $29.86
- MDGL $463.63
- Technical
- Relative Strength Index (RSI)
- CAG 31.89
- MDGL 46.87
- Support Level
- CAG $18.26
- MDGL $393.61
- Resistance Level
- CAG $18.99
- MDGL $434.48
- Average True Range (ATR)
- CAG 0.39
- MDGL 16.23
- MACD
- CAG -0.12
- MDGL -2.55
- Stochastic Oscillator
- CAG 9.43
- MDGL 51.20
About CAG ConAgra Brands Inc.
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.